Tirzepatide vs IGF-1 LR3
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
TirzepatideAnabolic & IGF
IGF-1 LR3- Summary
- Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist that produces greater weight loss than semaglutide in head-to-head trials. SURMOUNT-1 trial showed average 21% body weight reduction at 72 weeks at the highest dose. Marketed as Mounjaro (diabetes) and Zepbound (obesity).
- IGF-1 LR3 is a synthetic analog of Insulin-like Growth Factor-1 with an extended half-life. It is one of the most potent anabolic peptides available, directly stimulating muscle cell hyperplasia and hypertrophy, and is the downstream mediator of many of GH's anabolic effects.
- Half-Life
- ~5 days
- 20–30 hours
- Admin Route
- SubQ
- SubQ, IM
- Research
- —
- —
- Typical Dose
- 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg
- 40–80 mcg
- Frequency
- Once weekly, subcutaneous
- Once daily or split twice daily
- Key Benefits
- Average 21% body weight reduction at highest dose (SURMOUNT-1)
- Superior to semaglutide in head-to-head SURPASS trials
- Dual GIP/GLP-1 mechanism for enhanced metabolic control
- Significant reduction in HbA1c for type 2 diabetes
- Improved cardiovascular risk markers
- Reduces visceral fat preferentially
- FDA-approved for T2DM (Mounjaro) and obesity (Zepbound)
- Weekly dosing
- Direct muscle hypertrophy via IGF-1R stimulation
- Muscle hyperplasia (new fiber formation) — unique among peptides
- Rapid gains in lean muscle mass
- Accelerated recovery from training and injury
- Increased nutrient uptake by muscle cells
- Fat oxidation enhancement
- Bone density improvement
- Cartilage and connective tissue repair
- Side Effects
- Nausea (most common during titration)
- Vomiting
- Diarrhea or constipation
- Abdominal pain
- +3 more
- Hypoglycemia (significant risk — insulin-like activity)
- Acromegaly-like effects with excessive long-term use
- Jaw and hand swelling
- Organ hypertrophy with extreme doses
- +2 more
- Stacks With
- —
- —